Literature DB >> 20812848

Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation.

Reena Rajasuriar1, David Booth, Ajantha Solomon, Kyra Chua, Tim Spelman, Maelenn Gouillou, Timothy E Schlub, Miles Davenport, Suzanne Crowe, Julian Elliott, Jennifer Hoy, Christopher Fairley, Graeme Stewart, Paul Cameron, Sharon R Lewin.   

Abstract

BACKGROUND: Multiple host factors may influence CD4(+) T cell reconstitution in human immunodeficiency virus (HIV)-infected patients after suppressive antiretroviral therapy (ART). We hypothesized that residual immune activation and polymorphisms in the interleukin 7 (IL-7) receptor α (IL-7Rα) gene were important for immune recovery.
METHODS: We examined HIV-infected patients receiving suppressive ART (n = 96) for their IL-7Rα haplotypes and measured levels of lipopolysaccharide (LPS), soluble CD14, and IL-7 in plasma samples collected before and after ART initiation. Levels of soluble IL-7Rα were measured in HIV-infected patients with IL-7Rα haplotype 2 (n = 11) and those without IL-7Rα haplotype 2 (n = 22). Multivariate analysis was used to identify variables associated with faster recovery to CD4(+) T cell counts of >500 and >200 cells/μL.
RESULTS: Both LPS and soluble CD14 levels were significantly decreased with ART (P < .001, respectively) but remained elevated compared with uninfected controls. In a multivariate analysis, faster recovery to a CD4(+) T cell count of >500 cells/μL was significantly associated with higher baseline CD4(+) T cell count, younger age, lower pre-ART LPS level, higher pre-ART soluble CD14 level, lower pre-ART IL-7 level, and IL-7Rα haplotype 2 (hazard ratio, 1.50; 95% confidence interval, 1.03-2.19; P = .034). HIV-infected patients with haplotype 2 had significantly lower soluble IL-7Rα levels compared with those of patients without haplotype 2 (P < .001).
CONCLUSION: Both the extent of immune depletion prior to ART and IL-7Rα haplotype 2 are important determinants of time to CD4(+) T cell recovery to counts of >500 cells/μL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20812848     DOI: 10.1086/656369

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  58 in total

1.  Novel sensitive real-time PCR for quantification of bacterial 16S rRNA genes in plasma of HIV-infected patients as a marker for microbial translocation.

Authors:  M Kramski; A J Gaeguta; G F Lichtfuss; R Rajasuriar; S M Crowe; M A French; S R Lewin; R J Center; D F J Purcell
Journal:  J Clin Microbiol       Date:  2011-08-03       Impact factor: 5.948

2.  Effect of baseline micronutrient and inflammation status on CD4 recovery post-cART initiation in the multinational PEARLS trial.

Authors:  Rupak Shivakoti; Erin R Ewald; Nikhil Gupte; Wei-Teng Yang; Cecilia Kanyama; Sandra W Cardoso; Breno Santos; Khuanchai Supparatpinyo; Sharlaa Badal-Faesen; Javier R Lama; Umesh Lalloo; Fatima Zulu; Jyoti S Pawar; Cynthia Riviere; Nagalingeswaran Kumarasamy; James Hakim; Richard Pollard; Barbara Detrick; Ashwin Balagopal; David M Asmuth; Richard D Semba; Thomas B Campbell; Jonathan Golub; Amita Gupta
Journal:  Clin Nutr       Date:  2018-05-29       Impact factor: 7.324

3.  Decreases in IL-7 levels during antiretroviral treatment of HIV infection suggest a primary mechanism of receptor-mediated clearance.

Authors:  Jessica N Hodge; Sharat Srinivasula; Zonghui Hu; Sarah W Read; Brian O Porter; Insook Kim; Joann M Mican; Chang Paik; Paula Degrange; Michele Di Mascio; Irini Sereti
Journal:  Blood       Date:  2011-07-21       Impact factor: 22.113

Review 4.  Inflammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing.

Authors:  Anna C Hearps; Genevieve E Martin; Reena Rajasuriar; Suzanne M Crowe
Journal:  Curr HIV/AIDS Rep       Date:  2014-03       Impact factor: 5.071

5.  Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy.

Authors:  Tuan Le; Edwina J Wright; Davey M Smith; Weijing He; Gabriel Catano; Jason F Okulicz; Jason A Young; Robert A Clark; Douglas D Richman; Susan J Little; Sunil K Ahuja
Journal:  N Engl J Med       Date:  2013-01-17       Impact factor: 91.245

Review 6.  Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy.

Authors:  Babafemi Taiwo; Luis Barcena; Randall Tressler
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

Review 7.  Microbial translocation, immune activation, and HIV disease.

Authors:  Nichole R Klatt; Nicholas T Funderburg; Jason M Brenchley
Journal:  Trends Microbiol       Date:  2012-10-11       Impact factor: 17.079

Review 8.  Microbial translocation in HIV infection: causes, consequences and treatment opportunities.

Authors:  Netanya G Sandler; Daniel C Douek
Journal:  Nat Rev Microbiol       Date:  2012-08-13       Impact factor: 60.633

Review 9.  Immune activation and HIV persistence: implications for curative approaches to HIV infection.

Authors:  Nichole R Klatt; Nicolas Chomont; Daniel C Douek; Steven G Deeks
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

Review 10.  HIV and co-infections.

Authors:  Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.